4.7 Article

Tedizolid as Step-Down Therapy following Daptomycin versus Continuation of Daptomycin against Enterococci and Methicillin- and Vancomycin-Resistant Staphylococcus aureus in a Rat Endocarditis Model

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 5, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02303-19

Keywords

tedizolid; daptomycin; E. faecalis; E. faecium; MRSA/VRSA; experimental endocarditis; enterococci; staphylococci

Funding

  1. Merck, Inc.
  2. NIAID [R21AI133289-01A1]
  3. [K24-AI121296]
  4. [R01AI134637]
  5. [R21AI143229]

Ask authors/readers for more resources

Tedizolid (TZD) and daptomycin (DAP) were assessed in a rat endocarditis model against Enterococcus faecalis, Enterococcus faecium (resistant to vancomycin and ampicillin), and Staphylococcus aureus. As a monotherapy, TZD for 5 days was not effective in a comparison with no-treatment controls, while DAP for 5 days was significantly effective against these bacteria. Step-down therapy (DAP for 3 days followed by TZD for 2 days) was as effective as DAP for 5 days and was comparable to 3 days of DAP plus ceftriaxone against all bacteria and to 3 days of DAP plus gentamicin against E. faecalis OG1RF.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available